To learn more about the top medical innovations for 2022, please visit [ Ссылка ]
Each year, more than 200,000 American men receive a diagnosis of prostate cancer – making it the most commonly diagnosed cancer among men in the United States. Accurate imaging is critical for tumor localization, staging the disease and detecting recurrences. PSMA, an antigen found in high levels on the surface of prostate cancer cells, is a potential biomarker for the disease. PMSA PET scans use a radioactive tracer to attach to PSMA proteins, which are then combined with CT or MRI scans to visualize the location of prostate cancer cells. In 2020, this technology received FDA approval based on Phase III clinical trials, which showed substantially increased accuracy for detecting prostate cancer metastasis compared to conventional imaging with bone and CT scans. When detected early by PSMA PET scans, recurrent prostate cancer can be treated through a targeted approach with stereotactic body radiation therapy, surgery and/or systemic therapy in a personalized manner.
▶Share this video with others: [ Ссылка ]
▶Subscribe to learn more about Cleveland Clinic:
[ Ссылка ]
#ClevelandClinic #MedicalInnovations
PSMA-Targeted Therapy in Prostate Cancer
Теги
medical innovations 2022cleveland clinic innovationstop 10 medical innovationsmedical innovations from cleveland clinicmedical innovationstop 10 medical innovation 2022top 10 medical innovation cleveland clinic4219cleveland clinicthe top 10 most promising medical technologiesPSMA targeted therapypsma targeted therapy for prostate cancerpsma targeted therapyprostate cancer treatmentpsma pet scan prostate cancer